Strong first quarter provides momentum for Biomet in 2005-06
This article was originally published in Clinica
Fiscal 2005 has started off favourably for US orthopaedics company Biomet as it reported a first quarter profit of $0.36 per share - a 20% increase from last year's results and one cent higher than analysts' consensus estimates. The results were adjusted to exclude costs relating to its acquisition of Merck KgaA's interest in the Biomet/Merck joint venture at the end of last year (see Clinica No 1089, p 12) and of Interpore International in June this year (see Clinica No 1113, p 14).
You may also be interested in...
Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.